Targeted probes for cardiovascular MRI

Future Medicinal Chemistry

Volumn 2, Issue 3, 2010, Pages 451-470

  Uppal, Ritika ^a   Caravan, Peter ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; APOLIPOPROTEIN E; CELL SURFACE RECEPTOR; EP 2104 R; EP 3533; GADODIAMIDE; GADOFLUORINE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLYPEPTIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM EXAMINATION; CONTRAST RADIOGRAPHY; CROSS LINKING; DIAGNOSTIC IMAGING; DRUG SYNTHESIS; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; MACROPHAGE; MICELLE; MOLECULAR IMAGING; MOLECULAR MECHANICS; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT RESPONSE;

AMINO ACID SEQUENCE; APOPTOSIS; CARDIOVASCULAR SYSTEM; CONTRAST MEDIA; FERRIC COMPOUNDS; GADOLINIUM; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; MOLECULAR PROBES; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; PEPTIDES;

EID: 77953425066     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.154     Document Type: Review

References (95)

1. Caravan P, Lauffcr RB. Contrast agents: basic principles. In: Clinical Magnetic Resonance Imaging. Edelman RR, Hesselink JR, Zlatkin MB, Crues JV (Eds). Saunders, Philadelphia, USA, 357-375 (2005).
2. Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J. Magn. Reson. Imaging 19(6), 771-788 (2004).
3. Goyen M, Edelman M, Perreault P et al. MR angiography of aortoiliac occlusive disease: a Phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236(3), 825-833 (2005).
4. Caravan P, Parigi G, Chasse JM et al. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium.(III)-based magnetic resonance angiography contrast agent. Inorg. Chem. 46(16), 6632-6639 (2007).
5. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest. Radiol. 41(3), 229-243 (2006).
6. Weissleder R, Mahmood U. Molecular imaging. Radiology 219(2), 316-333. (2001).
7. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 115(15), 2076-2086 (2007).
8. Nahrendorf M, Jaffer FA, Kelly KA et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14), 1504-1511 (2006).
9. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ. Ras. 94(4), 433-445 (2004).
10. Sosnovik DE. Molecular imaging in cardiovascular magnetic resonance imaging: current perspective and future potential. Top. Magn. Reson. Imaging 19(1), 59-68 (2008).
11. Laurent S, Forge D, Port: M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064-2110 (2008).
12. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60(11), 1241-1251 (2008).
13. Sosnovik DE, Nahrendorf M, Weissleder R. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res. Cardiol. 103(2), 122-130 (2008).
14. Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107(18), 2290-2293 (2003).
15. Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic imaging of allogeneic mesenchymal stem, cells trafficking to myocardial, infarction. Circulation 112(10), 1451-1461 (2005).
16. Thorek DL, Chen. AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34(1), 23-38 (2006).
17. Korosoglou G, Weiss RG, Kedziorek DA et al. Non invasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using 'positive contrast' magnetic resonance imaging. J. Am. Coll. Cardiol. 52(6), 483-491 (2008).
18. Reynolds PR, Larkman DJ, Haskard DO et al. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology 241(2), 469-476 (2006).
19. Flacke S, Fischer S, Scott MJ et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104(11), 1280-1285 (2001).
20. Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fujii. DK. A. targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J. Magn. Reson. Imaging 13(4), 615-618 (2001).
21. Sosnovik DE, Schellenberger EA, Nahrendorf M et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54(3), 718-724 (2005).
22. McAteer MA, Schneider JE, Ali ZA et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vase. Biol. 28(1), 77-83 (2008).
23. von zur Muhlen C, von Elverfeldt D, Moeller JA et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 118(3), 258-267(2008).
24. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J. Am. Coll. Cardiol. 46(6), 937-954 (2005). (Pubitemid 41316498)
25. Shah PK, Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog. Cardiovasc. Dis. 44(5), 357-368 (2002).
26. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv. Cardiol. 15(6), 439-446 (2002).
27. Libby P. Inflammation in atherosclerosis. Nature 420 (6917), 868-874 (2002).
28. Lanza GM, Abendschein DR, Yu X et al. Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. Acad. Radiol. 9(Suppl. 2), S330-S331 (2002).
29. Trivedi RA, U-King-Im JM, Graves MJ et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35(7), 1631-1635 (2004).
30. Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107(19), 2453-2458 (2003).
31. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging5(2), 85-92 (2006).
32. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005).
33. Stuber M, Gilson WD, Schar M et al. Positive contrast visualization of iron oxide-labeled stern cells using inversion-recovery with ON-resonant water suppression (IRON). Magn. Reson. Med. 58(5), 1072-1077 (2007).
34. Farrar CT, Dai G, Novikov M et al. Impact of field strength and iron oxide nanoparticle concentration on the linearity and diagnostic accuracy of off-resonance imaging. NMR Biomed. 21(5), 453-463 (2008).
35. Tsourkas A, Shinde-Patil VR, Kelly KA et al. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug. Chem. 16(3), 576-581 (2005).
36. Kelly KA, Allport JR, Tsourkas A, ShindePatil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96(3), 327-336 (2005).
37. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ. Res. 86(1.1), 1107-1113 (2000).
38. Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182(2), 381-385 (1992).
39. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21(4), 469-490 (2008).
40. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247(3), 608-612 (2008).
41. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur. J. Radiol. 66(2), 180-183 (2008).
42. Lancelot E, Amirbekian V, Brigger I et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler. Thromb. Vase. Biol. 28(3), 425-432 (2008).
43. Amirbekian V, Aguinaldo JG, Amirbekian S etal. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 251(2), 429-438 (2009).
44. Helm PA, Caravan P, French BA. et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 247(3), 788-796 (2008).
45. Caravan P, Das B, Dumas S et al. Collagentargeted MRI contrast agent for molecular imaging of fibrosis. Angew. Chem. Int. Ed. Engl. 46(43), 8171-8173 (2007).
46. Caravan P, Das B, Deng Q et al. A lysine walk to high relaxivity collagen-targeted MRI contrast: agents. Chem. Commun. (Camb) (4), 430-432 (2009).
47. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am. J. Med. 113(8), 668-680 (2002).
48. Botnar RM, Perez AS, Witte S et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 109(16), 2023-2029 (2004).
49. Overoye-Chan K, Koerner S, Looby RJ et al. EP-2104R: a fibrin-specific gadoliniumbased MRI contrast agent for detection of thrombus. J Am. Chem. Soc. 130(18), 6025-6039 (2008).
50. Sirol M, Aguinaldo JG, Graham PB et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 182(1), 79-85 (2005).
51. Spuentrup E, Katoh M, Buecker A et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest. Radiol. 42(8), 586-595 (2007).
52. Spuentrup E, Katoh M, Wiethoff AJ et al. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am. J. Respir. Crit. Care Med. 172(4), 494-500(2005).
53. Spuentrup E, Fausten B, Kinzel S et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation 112(3), 396-399 (2005).
54. Spuentrup E, Buecker A, Katoh M et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 111(11), 1377-1382 (2005).
55. Botnar RM, Buecker A, Wiethoff AJ et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 110(11), 1463-1466 (2004).
56. Spuentrup E, Botnar RM, Wiethoff AJ et al. MR imaging of thrombi, using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur. Radiol. 18(9), 1995-2005 (2008).
57. Nair SA, Kolodziej AF, Bhole G, Greenfield MT, McMurry TJ, Caravan P. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. Angew. Chem. Int. Ed. Engl. 47(26), 4918-4921 (2008).
58. Morawski AM, Winter PM, Yu X et al. Quantitative 'magnetic resonance immunohistochemistry' with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 52(6), 1255-1262(2004).
59. Sanders HM, Strijkers GJ, Mulder WJ et al. Morphology, binding behavior and MR-properties of paramagnetic collagenbinding liposomes. Contrast Media Mol. Imaging4(2), 81-88 (2009).
60. Amirbekian V, Lipinski MJ, Briley-Saebo KC et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104(3), 961-966 (2007).
61. Mulder WJ, Douma K, Konirig GA et al. Liposome-erihanced MRI of neointimal lesions in the ApoE-KO mouse. Magn. Reson. Med. 55(5), 1170-1174(2006).
62. Winter PM, Morawski AM, Caruthers SD et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with a-(v)-ß-3integrin- targeted nanoparticles. Circulation 108(18), 2270-2274 (2003).
63. Lipinski MJ, Amirbekian V, Frias JC et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn. Reson. Med. 56(3), 601-610 (2006).
64. Briley-Saebo KC, Shaw PX, Mulder WJ et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117(25), 3206-3215 (2008).
65. Meding J, Urich M, Licha K et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with gadofluorine M. Contrast Media Mol. Imaging 2(3), 120-129 (2007).
66. Zheng J, Ochoa E, Misselwitz B et al. Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest. Radiol. 43(1), 49-55 (2008).
67. Koktzoglou I, Harris KR, Tang R et al. Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest. Radiol. 41(3), 299-304 (2006).
68. Sirol M, Itskovich VV, Mani V et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109(23), 2890-2896 (2004).
69. Barkhausen J, Ebert W, Heyer C, Debatin JF, Weinmann HJ. Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging. Circulation 108(5), 605-609 (2003).
70. Ronald JA, Chen JW, Chen Y et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 120(7), 592-599 (2009).
71. Chen JW, Pham W, Weissleder R, Bogdanov AJr. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn. Reson. Med. 52(5), 1021-1028 (2004).
72. Querol M, Bennett DG, Sotak C, Kang HW Bogdanov A Jr. A paramagnetic contrast agent for detecting tyrosinase activity. ChemBioChem. 8(1.4), 1637-1641 (2007).
73. Tung CH, Ho NH, Zeng Q. et al. Novel factor XIII probes for blood, coagulation imaging. ChemBioChem. 4(9), 897-899 (2003).
74. 3+ magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement Angew. Chem. Int. Ed. Engl. 40(15), 2903-2906 (2001).
75. Louie AY, Huber MM, Ahrens ET et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18(3), 321-325 (2000).
76. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88(4), 554-567 (2002).
77. Naruko T, Ueda M, Haze K et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106(23), 2894-2900 (2002).
78. Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349(17), 1595-1604(2003).
79. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vase. Biol. 25(6), 1102-1111 (2005).
80. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidasemediated oxidant in plaque erosion and thrombogenesis. Atreriscler. Thromb. Vase. Biol. 24(7), 1309-1314 (2004).
81. Querol M, Chen JW, Weissleder R, Bogdanov A Jr. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org. Lett. 7(9), 1719-1722 (2005).
82. Chen JW, Querol Sans M, Bogdanov A Jr. Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 240(2), 473-481 (2006).
83. Querol M, Chen JW, Bogdanov AA Jr. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Org. Biomol. Chem. 4(10), 1887-1895 (2006).
84. Nahrendorf M, Sosnovik D, Chen JW et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 117(9), 1153-1160(2008).
85. Yeon SB, Sabir A, Clouse M et al. Delayedenhancement cardiovascular magnetic resonance coronary artery wall imaging: comparison with multislice computed tomography and quantitative coronary angiography. J. Am. Coll. Cardiol. 50(5), 441-447 (2007).
86. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491-2499 (2003).
87. Winter PM, Neubauer AM, Caruthers SD etal. Endothelial α-(v)-β-3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vase. Biol. 26(9), 2103-2109 (2006).
88. Wchrl HF, Judenhofer MS, Wichr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research, Eur. J. Nucl. Med. Mol. Imaging 36(Suppl. 1), S56-S68 (2009).
89. Schlemmer HP, Pichler BJ, Schmand M et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248(3), 1028-1035 (2008).
90. Catana C, Procissi D, Wu Y et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc. Natl Acad. Sci. USA 105(10), 3705-3710 (2008).
91. 19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr. Top. Dev. Biol. 70, 57-76 (2005).
92. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc. Natl Acad. Sci. USA 104(50), 19773-19777 (2007).
93. Olsson LE, Chai CM, Axelsson O, Karlsson M, Golman K, Petersson JS. MR coronary angiography in pigs with intraarterial injections of a hyperpolarized 13C substance. Magn. Reson. Med. 55(4), 731-737 (2006).
94. Sherry AD, Woods M, Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu, Rev. Biomed. Eng. 10, 391-411 (2008).
95. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 143(1), 79-87 (2000).